Published in J Virol on September 26, 2007
Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog (2009) 2.36
Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J Virol (2009) 1.80
Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther (2009) 1.59
Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci U S A (2011) 1.58
Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. J Virol (2008) 1.32
Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology (2013) 1.19
T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge. J Virol (2010) 1.11
Relevance of studying T cell responses in SIV-infected rhesus macaques. Trends Microbiol (2008) 1.05
The efficacy of T cell-mediated immune responses is reduced by the envelope protein of the chimeric HIV-1/SIV-KB9 virus in vivo. J Immunol (2008) 0.85
Balancing reversion of cytotoxic T-lymphocyte and neutralizing antibody escape mutations within human immunodeficiency virus type 1 Env upon transmission. J Virol (2009) 0.83
Antibody-Dependent Cellular Cytotoxicity and NK Cell-Driven Immune Escape in HIV Infection: Implications for HIV Vaccine Development. Adv Virol (2012) 0.82
Neuropathogenic SIVsmmFGb genetic diversity and selection-induced tissue-specific compartmentalization during chronic infection and temporal evolution of viral genes in lymphoid tissues and regions of the central nervous system. AIDS Res Hum Retroviruses (2010) 0.81
Linking pig-tailed macaque major histocompatibility complex class I haplotypes and cytotoxic T lymphocyte escape mutations in simian immunodeficiency virus infection. J Virol (2014) 0.78
HIV-1 Transmission, Replication Fitness and Disease Progression. Virology (Auckl) (2008) 0.78
Association of lymph-node antigens with lower Gag-specific central-memory and higher Env-specific effector-memory CD8(+) T-cell frequencies in a macaque AIDS model. Sci Rep (2016) 0.75
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 21.24
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol (1994) 15.93
Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75
CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med (2006) 10.34
HIV evolution: CTL escape mutation and reversion after transmission. Nat Med (2004) 10.21
Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med (2004) 6.33
Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med (1997) 5.72
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med (2005) 5.68
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis (2006) 5.53
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A (2005) 3.94
AIDS vaccine models: challenging challenge viruses. Nat Med (2002) 3.92
An HIV vaccine--evolving concepts. N Engl J Med (2007) 3.78
T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity (2004) 3.69
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis (2006) 3.40
Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol (2005) 3.03
Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine (2007) 2.68
Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci U S A (2004) 2.51
Redundancy, antiredundancy, and the robustness of genomes. Proc Natl Acad Sci U S A (2002) 2.42
Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol (2005) 2.25
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol (2002) 2.13
The rational design of an AIDS vaccine. Cell (2006) 2.11
Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge. J Virol (2003) 1.70
Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. J Virol (2005) 1.63
A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine (2006) 1.48
Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. J Virol (2004) 1.39
Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model. AIDS Res Hum Retroviruses (2006) 1.21
Reversion of immune escape HIV variants upon transmission: insights into effective viral immunity. Trends Microbiol (2005) 1.21
Vaccine-induced T cells control reversion of AIDS virus immune escape mutants. J Virol (2007) 1.19
Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques. J Virol (2006) 1.15
In vivo fitness costs of different Gag CD8 T-cell escape mutant simian-human immunodeficiency viruses for macaques. J Virol (2007) 1.11
Fitness constraints on immune escape from HIV: Implications of envelope as a target for both HIV-specific T cells and antibody. Curr HIV Res (2006) 0.95
Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol (2005) 3.03
Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci U S A (2012) 2.64
Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol (2013) 1.95
Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol (2008) 1.83
Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci U S A (2011) 1.58
Rapid degranulation of NK cells following activation by HIV-specific antibodies. J Immunol (2009) 1.57
Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J Virol (2013) 1.53
Analysis of pigtail macaque major histocompatibility complex class I molecules presenting immunodominant simian immunodeficiency virus epitopes. J Virol (2005) 1.52
Vaccination and timing influence SIV immune escape viral dynamics in vivo. PLoS Pathog (2008) 1.34
A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS (2006) 1.33
The utility of ADCC responses in HIV infection. Curr HIV Res (2008) 1.30
Activation of NK cells by ADCC antibodies and HIV disease progression. J Acquir Immune Defic Syndr (2011) 1.24
Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J Virol (2005) 1.23
High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J Immunol (2009) 1.22
MHC class I allele frequencies in pigtail macaques of diverse origin. Immunogenetics (2006) 1.21
Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques. J Virol (2013) 1.21
Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model. AIDS Res Hum Retroviruses (2006) 1.21
Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology (2013) 1.19
Vaccine-induced T cells control reversion of AIDS virus immune escape mutants. J Virol (2007) 1.19
The pigtail macaque MHC class I allele Mane-A*10 presents an immundominant SIV Gag epitope: identification, tetramer development and implications of immune escape and reversion. J Med Primatol (2005) 1.15
Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques. J Virol (2006) 1.15
Rates of HIV immune escape and reversion: implications for vaccination. Trends Microbiol (2008) 1.14
NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. Viral Immunol (2011) 1.13
Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques. Virology (2002) 1.12
In vivo fitness costs of different Gag CD8 T-cell escape mutant simian-human immunodeficiency viruses for macaques. J Virol (2007) 1.11
Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood. PLoS Pathog (2008) 1.10
Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1. J Infect Dis (2013) 1.10
Killing kinetics of simian immunodeficiency virus-specific CD8+ T cells: implications for HIV vaccine strategies. J Immunol (2007) 1.07
Screening and confirmatory testing of MHC class I alleles in pig-tailed macaques. Immunogenetics (2011) 1.05
Quantification of simian immunodeficiency virus cytotoxic T lymphocyte escape mutant viruses. AIDS Res Hum Retroviruses (2008) 1.05
Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials. Vaccine (2005) 1.04
Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. Vaccine (2005) 1.02
A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules. ACS Nano (2009) 1.02
HIV infection abrogates the functional advantage of natural killer cells educated through KIR3DL1/HLA-Bw4 interactions to mediate anti-HIV antibody-dependent cellular cytotoxicity. J Virol (2012) 1.02
Timing of immune escape linked to success or failure of vaccination. PLoS One (2010) 1.00
CD4+ target cell availability determines the dynamics of immune escape and reversion in vivo. J Virol (2008) 1.00
Activation of NK cells by ADCC responses during early HIV infection. Viral Immunol (2011) 1.00
The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection. Hepatology (2007) 1.00
Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J Virol (2009) 0.99
Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques. J Virol (2013) 0.99
Induction of T-cell immunity to antiretroviral drug-resistant human immunodeficiency virus type 1. J Virol (2005) 0.99
Peripheral NKT cells in simian immunodeficiency virus-infected macaques. J Virol (2008) 0.98
Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine (2009) 0.98
Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques. J Virol (2009) 0.96
Natural host genetic resistance to lentiviral CNS disease: a neuroprotective MHC class I allele in SIV-infected macaques. PLoS One (2008) 0.96
Anti-HIV antibody-dependent activation of NK cells impairs NKp46 expression. J Immunol (2013) 0.95
Fitness constraints on immune escape from HIV: Implications of envelope as a target for both HIV-specific T cells and antibody. Curr HIV Res (2006) 0.95
Does cytolysis by CD8+ T cells drive immune escape in HIV infection? J Immunol (2010) 0.94
CD127+CCR5+CD38+++ CD4+ Th1 effector cells are an early component of the primary immune response to vaccinia virus and precede development of interleukin-2+ memory CD4+ T cells. J Virol (2006) 0.94
Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology (2011) 0.92
Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques. Vaccine (2005) 0.92
Replication-competent simian immunodeficiency virus (SIV) Gag escape mutations archived in latent reservoirs during antiretroviral treatment of SIV-infected macaques. J Virol (2011) 0.92
The role of HIV-specific antibody-dependent cellular cytotoxicity in HIV prevention and the influence of the HIV-1 Vpu protein. AIDS (2015) 0.91
HIV-specific antibody immunity mediated through NK cells and monocytes. Curr HIV Res (2013) 0.90
Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNgamma or IL-12. Vaccine (2004) 0.90
Virus-specific T-cell immunity correlates with control of GB virus B infection in marmosets. J Virol (2007) 0.89
Substantial envelope-specific CD8 T-cell immunity fails to control SIV disease. Virology (2008) 0.89
Limited maintenance of vaccine-induced simian immunodeficiency virus-specific CD8 T-cell receptor clonotypes after virus challenge. J Virol (2008) 0.89
Complexity of the inoculum determines the rate of reversion of SIV Gag CD8 T cell mutant virus and outcome of infection. PLoS Pathog (2009) 0.89
Low pre-infection levels and loss of central memory CD4+ T cells may predict rapid progression in SIV-infected pigtail macaques. Virology (2008) 0.88
Obstacles to ideal anti-HIV antibody-dependent cellular cytotoxicity responses. Vaccine (2013) 0.88
Safety, immunogenicity and efficacy of peptide-pulsed cellular immunotherapy in macaques. J Med Primatol (2008) 0.88
Delivery of immunotherapy with peptide-pulsed blood in macaques. Virology (2008) 0.87
Thrombocytopenia is strongly associated with simian AIDS in pigtail macaques. J Acquir Immune Defic Syndr (2009) 0.87
Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates. Eur J Immunol (2015) 0.87
Anti-HIV-1 antibody-dependent cellular cytotoxicity mediated by hyperimmune bovine colostrum IgG. Eur J Immunol (2012) 0.86
Differential patterns of immune escape at Tat-specific cytotoxic T cell epitopes in pigtail macaques. Virology (2009) 0.86
Influence of cytokines on HIV-specific antibody-dependent cellular cytotoxicity activation profile of natural killer cells. PLoS One (2012) 0.86
HIV-specific antibody-dependent cellular cytotoxicity: a novel vaccine modality. Expert Rev Clin Immunol (2012) 0.86
Decreased neurotropism of nef long terminal repeat (nef/LTR)-deleted simian immunodeficiency virus. J Neurovirol (2003) 0.86
Trivalent live attenuated influenza-simian immunodeficiency virus vaccines: efficacy and evolution of cytotoxic T lymphocyte escape in macaques. J Virol (2013) 0.86
Prime-boost strategies in DNA vaccines. Methods Mol Med (2006) 0.86
Vaccines and vaccine strategies against HIV. Curr Drug Targets (2004) 0.85
HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity. Hum Vaccin (2011) 0.84
Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity: relevance to global HIV vaccine design. AIDS (2014) 0.84
Balancing reversion of cytotoxic T-lymphocyte and neutralizing antibody escape mutations within human immunodeficiency virus type 1 Env upon transmission. J Virol (2009) 0.83
The high cost of fidelity. AIDS Res Hum Retroviruses (2014) 0.83
Comparison of influenza and SIV specific CD8 T cell responses in macaques. PLoS One (2012) 0.83
Polymorphisms and interspecies differences of the activating and inhibitory FcγRII of Macaca nemestrina influence the binding of human IgG subclasses. J Immunol (2013) 0.82
A paradigm for peptide vaccine delivery using viral epitopes encapsulated in degradable polymer hydrogel capsules. Biomaterials (2009) 0.82
Granulocyte contamination dramatically inhibits spot formation in AIDS virus-specific ELISpot assays: analysis and strategies to ameliorate. J Immunol Methods (2005) 0.82
Antibody-Dependent Cellular Cytotoxicity and NK Cell-Driven Immune Escape in HIV Infection: Implications for HIV Vaccine Development. Adv Virol (2012) 0.82
Accelerating the development of an AIDS vaccine: the AIDS vaccine for Asia Network (Avan). Southeast Asian J Trop Med Public Health (2011) 0.82
Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines: implications for future trials. Hum Vaccin (2006) 0.82
Role of education and differentiation in determining the potential of natural killer cells to respond to antibody-dependent stimulation. AIDS (2014) 0.81
Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia. Curr Opin HIV AIDS (2010) 0.81
CD4+ T-cell subsets: what really counts in preventing HIV disease? Expert Rev Vaccines (2008) 0.80
An "escape clock" for estimating the turnover of SIV DNA in resting CD4⁺ T cells. PLoS Pathog (2012) 0.80
Loss of control of HIV viremia associated with the fat malabsorption drug orlistat. AIDS Res Hum Retroviruses (2012) 0.79
Genetic influences on HIV infection: implications for vaccine development. Sex Health (2005) 0.79
The role of T cell immunity in HIV-1 infection. Curr Opin Virol (2013) 0.79
Protection afforded by live attenuated SIV is associated with rapid killing kinetics of CTLs. J Med Primatol (2008) 0.79
Inactivated simian immunodeficiency virus-pulsed autologous fresh blood cells as an immunotherapy strategy. J Virol (2008) 0.79
Characterisation of simian immunodeficiency virus-infected cells in pigtail macaques. Virology (2012) 0.79
Ex-vivo α-galactosylceramide activation of NKT cells in humans and macaques. J Immunol Methods (2012) 0.78
Activation of NK cells by HIV-specific ADCC antibodies: role for granulocytes in expressing HIV-1 peptide epitopes. Hum Vaccin Immunother (2013) 0.78
Characterization of the kynurenine pathway and quinolinic Acid production in macaque macrophages. Int J Tryptophan Res (2013) 0.78
Characterisation of macaque testicular leucocyte populations and T-lymphocyte immunity. J Reprod Immunol (2013) 0.78
Mechanically tunable, self-adjuvanting nanoengineered polypeptide particles. Adv Mater (2013) 0.78